Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients

doi:10.4251/wjgo.v1.i1.47

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4844)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

499

HTML

3346

Figures (1-1)

542

Tables (1-3)

457

Sum=4844

Oct 15, 2009 (publication date) through Dec 17, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Oct 15, 2009; 1(1): 47-54
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.47

Open in New Tab Full Size Figure Download Figure

Figure 1 Phase III trials are the most successful for far advanced gastric cancer in Europe (A) and in both United States and Japan (B). Arrows show chronological direction. BSC: Best supportive care; FAMTX: 5-FU/Adriamycin/Methotrexate; CF: Cisplatin/5-FU; ELF: Etoposide/Leucovorin/5-FU; FAM: 5-FU/Adriamycin/Mitomycin-C; ECF: Epirubicin/Cisplatin/5-FU; EOX: Epirubicin/Oxaliplatin/Capecitabine; DCF: Docetaxel/Cisplatin/5-FU; EORTC: European Organization for Research and Treatment of Cancer; RMH: Royal Marsden Hospital; SAKK: Swiss Group for Clinical Cancer Research; ns: Not significant. UFTM: UFT/Mitomycin-C; CS: S-1/Cisplatin; ¹CS regimens in the FLAGS study used 25 mg/m² of S-1 differently from the SPILITS trial (40 mg/m² of S-1).

Citation: Sakuramoto S, Yamashita K, Watanabe M. Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World J Gastrointest Oncol 2009; 1(1): 47-54
URL: https://www.wjgnet.com/1948-5204/full/v1/i1/47.htm
DOI: https://dx.doi.org/10.4251/wjgo.v1.i1.47